#APLT

Applied Therapeutics Announces Corporate Updates Applied Therapeutics (Nasdaq: APLT) announced that its Board has initiated a process to explore strategic alternatives including mergers, acquisitions, partnerships, licensing or other transactions to maximize shareholder value.The Company said it reduced its workforce by approximately 46% and is implementing other cost‑containment and cash conservation measures to preserve runway. The Board completed a Type C meeting with the FDA on govorestat for CMT‑SORD in Q3 2025 and expects to request an additional Type C to discuss a potential Phase 3 design. The Company also accepted FDA written feedback on govorestat data for Classic Galactosemia and is evaluating next steps. No timetable or assurance of a transaction was provided.

3 months ago

#APLT Applied Therapeutics Announces Corporate Updates

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Leading Indicators, Thursday November 13, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Thu Nov 13th - #WVE #SVCO #REE #PENG #OMER #MOGO #LFMD #IIIV #HTLD #VUZI #FIP #DGII #CLPS #BIRD #APLT #DHX #CTEV #AAUC - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Applied Therapeutics Reports Third Quarter 2025 Financial Results – Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes – Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia – New data on govorestat for the treatment of PMM2-CDG published

4 months ago

#APLT Applied Therapeutics Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

InsiderFinance

@insiderfinance.com

4 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CNXC, #TE, #ON, #CSIQ, #APLT

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Kulturdesken

@kulturdesken.bsky.social

5 months ago

#APLT
Catalysts: the company outlined plans for a pivotal Phase 3 trial of govorestat (CMT-SORD deficiency) and resolved prior securities litigation tied to its 2022 FDA rejection.

0 0 1 0

Stock Master

@stockmaster70.bsky.social

5 months ago

📢 Stocks Trending NOW: #TLRY #CGC #EA #GPUS #MLTX #BMNR #CCL #JFB #APLT #GME

0 0 0 0

Applied Therapeutics Reports Second Quarter 2025 Financial Results Applied Therapeutics (NASDAQ:APLT) reported Q2 2025 financial results and significant progress across its rare disease pipeline. The company's lead program, govorestat for CMT-SORD treatment, advances with an upcoming FDA meeting in Q3 2025 to discuss potential NDA submission. The company presented promising 24-month clinical data showing slowed disease progression and launched a sponsored Sorbitol Assay program for patient identification.Financial highlights include cash position of $30.4M as of June 30, 2025, down from $79.4M in December 2024. Q2 2025 resulted in a net loss of $21.3M ($0.15 per share). The company secured an out-licensing agreement with Biossil for AT-001 and strengthened its leadership team with key promotions.

7 months ago

#APLT Applied Therapeutics Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

Applied Therapeutics Announces Key Leadership Appointments Applied Therapeutics (NASDAQ: APLT) has announced key leadership changes with the promotion of Dr. Evan Bailey to Chief Medical Officer (CMO) and Dottie Caplan to Executive Vice President of Patient Advocacy and Government Affairs. Dr. Bailey, previously SVP of Clinical Development, succeeds Dr. Riccardo Perfetti and will lead clinical development and medical affairs activities for govorestat in late-stage development programs. Dr. Bailey brings extensive experience from Vertex Pharmaceuticals, where he led the TRIKAFTA launch for Cystic Fibrosis. Dottie Caplan, formerly SVP of Patient Advocacy and Engagement, will expand her role to include regulatory, legislative, and public policy functions. Both appointments are strategic moves to advance Applied's rare disease treatment portfolio, particularly focusing on govorestat's development for Classic Galactosemia, CMT-SORD, and PMM2-CDG.

8 months ago

#APLT Applied Therapeutics Announces Key Leadership Appointments

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

Applied Therapeutics Slashes Losses by $62M as Rare Disease Drug Shows Promise Net loss improves 74% YoY as Applied Therapeutics prepares to unveil crucial Phase 3 trial data for rare disease drug govorestat. See full financial details.

10 months ago

#APLT Applied Therapeutics Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting Applied Therapeutics (NASDAQ: APLT) announced that full 12-month clinical data from the INSPIRE Phase 3 trial of govorestat (AT-007) has been accepted for a late-breaking oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting in Edinburgh, Scotland. The presentation will also include new topline 18-month and 24-month data from patients before their transition to the open-label extension study.The INSPIRE Phase 3 trial was a double-blind, placebo-controlled registrational study evaluating govorestat's effect in patients with Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease. The company previously released topline results from the 12-month group-level data analysis in February 2024. ["-"]

10 months ago

#APLT Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

Applied Therapeutics Strengthens Balance Sheet: $79.4M Cash Position Powers Drug Development Push Latest earnings reveal stronger cash position and reduced losses, while new leadership team tackles FDA response for govorestat program. Full analysis inside.

11 months ago

#APLT Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results Clinical-stage biotech delays Form 10-K filing until April 15. Q4 and full-year 2024 earnings release pending new filing date confirmation. Full details inside.

11 months ago

#APLT Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission

www.stocktitan.net/news/APLT/applied-therap...

0 0 0 0

Investors Alert: Class Action Lawsuit Filed Against Applied Therapeutics, Inc. with a Deadline Approaching A class action lawsuit has been filed against Applied Therapeutics (APLT) for securities fraud. Investors affected between Jan-Dec 2024 can join before Feb 18, 2025.

1 year ago

Investors Alert: Class Action Lawsuit Filed Against Applied Therapeutics, Inc. with a Deadline Approaching #USA #New_York #Class_Action #Applied_Therapeutics #APLT

0 0 0 0

Investors of Applied Therapeutics Urged to Act in Class Action Filing by February 18, 2025 Applied Therapeutics investors facing significant losses can lead a class action lawsuit. Deadline for appointment is February 18, 2025. Join now.

1 year ago

Investors of Applied Therapeutics Urged to Act in Class Action Filing by February 18, 2025 #USA #San_Diego #Class_Action #Applied_Therapeutics #APLT

0 0 0 0

Important Notice for Applied Therapeutics, Inc. Investors: Legal Rights and Actions Explained Shareholders of Applied Therapeutics are urged to contact The Gross Law Firm regarding their rights due to declining stock prices and legal claims.

1 year ago

Important Notice for Applied Therapeutics, Inc. Investors: Legal Rights and Actions Explained #USA #New_York #Gross_Law_Firm #Applied_Therapeutics #APLT

0 0 0 0

Class Action Against Applied Therapeutics, Inc. with Deadline Approaching for Investors to Join Investors in Applied Therapeutics, Inc. face potential losses due to a recent class action lawsuit. The deadline to join is February 18, 2025.

1 year ago

Class Action Against Applied Therapeutics, Inc. with Deadline Approaching for Investors to Join #United_States #New_York #Class_Action #Applied_Therapeutics #APLT

0 0 0 0

Investors Alert: Lead Plaintiff Deadline Approaches for Applied Therapeutics Lawsuit A critical deadline approaches for Applied Therapeutics, Inc. shareholders regarding a class action lawsuit. Act before February 18, 2025 to join.

1 year ago

Investors Alert: Lead Plaintiff Deadline Approaches for Applied Therapeutics Lawsuit #United_States #New_York #Gross_Law_Firm #Applied_Therapeutics #APLT

0 0 0 0

Applied Therapeutics Faces Securities Lawsuit Over Major Stock Drop - Investors Urged to Take Action Investors in Applied Therapeutics, Inc. are encouraged to contact Levi & Korsinsky regarding potential legal action following significant stock declines. Don't miss this opportunity for your rights.

1 year ago

Applied Therapeutics Faces Securities Lawsuit Over Major Stock Drop - Investors Urged to Take Action #USA #New_York #securities_lawsuit #Applied_Therapeutics #APLT

0 0 0 0

Major Securities Law Suit Filed Against Applied Therapeutics: What Investors Need to Know Applied Therapeutics faces a lawsuit over alleged securities law violations. Investors who purchased shares during the specified period may want to act quickly.

1 year ago

Major Securities Law Suit Filed Against Applied Therapeutics: What Investors Need to Know #United_States #New_York #Gross_Law_Firm #Applied_Therapeutics #APLT

0 0 0 0

Investors Alert: Class Action Filed Against Applied Therapeutics, Inc. - APLT Shareholders Need to Act Now Attention investors! A class action lawsuit is currently underway against Applied Therapeutics, Inc. (APLT). Find out how to participate.

1 year ago

Investors Alert: Class Action Filed Against Applied Therapeutics, Inc. - APLT Shareholders Need to Act Now #USA #San_Diego #Robbins_LLP #Applied_Therapeutics #APLT

0 0 0 0

Levi & Korsinsky Calls for Lead Plaintiff in Applied Therapeutics Lawsuit Amid Securities Fraud Allegations Levi & Korsinsky announces a lead plaintiff deadline of February 18, 2025, for investors affected by alleged securities fraud in Applied Therapeutics.

1 year ago

Levi & Korsinsky Calls for Lead Plaintiff in Applied Therapeutics Lawsuit Amid Securities Fraud Allegations #United_States #New_York #Levi_&_Korsinsky #Applied_Therapeutics #APLT

0 0 0 0

Investors Alert: Lead Plaintiff Deadline Approaching for APLT Securities Fraud Lawsuit Investors in Applied Therapeutics should note the lead plaintiff deadline of February 18, 2025, for the class action lawsuit related to securities fraud. Don't miss your opportunity.

1 year ago

Investors Alert: Lead Plaintiff Deadline Approaching for APLT Securities Fraud Lawsuit #United_States #New_York #Levi_Korsinsky #Applied_Therapeutics #APLT

0 0 0 0